Nuvation Bio Inc. Long-Term Debt, Maturity, Year Three
Nuvation Bio Inc. (NUVB) had Long-Term Debt, Maturity, Year Three of $5.08 million as of 2026-03-31, per its 10-Q filed 2026-05-04.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2026-05-04
- 2026-03-31: Long-Term Debt, Maturity, Year Three $5.08M.
- 2025-12-31: Long-Term Debt, Maturity, Year Three $5.08M.
- 2025-09-30: Long-Term Debt, Maturity, Year Three $5.23M.
- 2025-06-30: Long-Term Debt, Maturity, Year Three $5.24M.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2026-03-31 | $5.08M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $5.08M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.23M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $5.24M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |